The Eden Prairie, Minn.-based company floated 2.2 million shares of its common stock at $2.12 per share and an additional 332,239 shares at the public offering price as part of a 45-day underwriter’s option to purchase additional shares.
Ladenburg Thalmann & Co acted as sole book-running manager for the offering, with Dawson James Securities acting as co-manager, according to a press release.
CHF Solutions said it plans to use net proceeds for general corporate purposes, including the expansion of its field sales force and commercial organization.
In May, CHF Solutions saw shares fall after the heart-focused medical device maker missed expectations on Wall Street with its first quarter earnings results.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.